Under construction – not a live service
Sign in
Not yet taking people in PolandNo phase

Snoezelen sensory therapy for adults with alcohol dependence or schizophrenia

Tests Snoezelen therapy in adults with schizophrenia or alcohol dependence.

Plain-language title generated from the registry record
Registry title: Snoezelen Therapy in Adults With Alcohol Dependence and Adults With Schizophrenia

Key facts

Where
Katowice and Rybnik, PolandSee the 2 sites

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with schizophrenia (some needing permanent institutional care) and women with alcohol dependence, to test Snoezelen therapy.

Age
18 years or older
Sex
Both women and men can join the schizophrenia groups. Only women can join the alcohol dependence group. Only men can join one of the schizophrenia groups.
Disease stage
Schizophrenia clinically confirmed, with mostly negative symptoms; one group needs at least 5 years of illness and permanent institutional care. Alcohol group: alcohol dependence syndrome (F10.2 in ICD-10) and a history of depressive and anxiety symptoms.
Earlier treatment
Schizophrenia groups need stable drug therapy: unchanged for at least 3 months in the institutional care group, at least 1 month in the other group.

Main reasons for not taking part

  • No consent to take part
  • Pregnancy (in the institutional care schizophrenia group and the alcohol group)
  • Worsening of the main illness, such as acute psychosis or severe anxiety
  • Unstable or untreated epilepsy, or active cancer
  • Other mental illness or drug use besides alcohol (alcohol group)

Read by machine on 9 November 2026.

Where in Poland

  • Jerzy Kukuczka Academy of Physical Education in Katowice, PolandKatowice, PolandNo longer taking part
  • Clinical Psychiatric Hospital SPZOZ in Rybnik, PolandRybnik, PolandNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
The Jerzy Kukuczka Academy of Physical Education in Katowice
Trial code
NCT07748078
Record updated
5 August 2026
Original description
The purpose of the study: obtaining knowledge about the impact of Snoezelen® therapy on the health of adults suffering from schizophrenia and requiring permanent institutional care, adults suffering from schizophrenia and adults (women) addicted to alcohol.Read full original descriptionShow less

Impact of Snoezelen Therapy in Adults With Alcohol Dependence and Adults With Schizophrenia

The purpose of the study: obtaining knowledge about the impact of Snoezelen® therapy on the health of adults suffering from schizophrenia and requiring permanent institutional care, adults suffering from schizophrenia and adults (women) addicted to alcohol.

The main questions it aims to answer are:

Does Snoezelen therapy improve the health of adults suffering from schizophrenia and requiring permanent institutional care, adults suffering from schizophrenia and adults (women) addicted to alcohol?

The participant will participate in Snoezelen® therapy for 6 or 12 weeks, 2 times a week (30 minutes each session).

Inclusion: women and men aged ≥ 18 years,; consent of the patient or legal guardian to participate in the study,; schizophrenia clinically confirmed for at least 5 years, with predominance of negative symptoms,; stable drug therapy (treatment unchanged for at least 3 months); ability to understand and follow the therapist's instructions,; functional ability of everyday life on the Barthel scale below 40 points,; men aged ≥ 18 years,; consent of the patient or legal guardian to participate in the study,; clinically confirmed schizophrenia with predominance of negative symptoms,; stable drug therapy (treatment unchanged for at least 1 month),; ability to understand and follow the therapist's instructions,; functional ability of everyday life on the Barthel scale above 40 points,; female gender; age ≥ 18 years; consent of the patient or legal guardian to participate in the study; alcohol dependence syndrome (F10.2 according to ICD-10); history of depressive and anxiety symptoms; ability to understand and follow the therapist's instructions; functional ability of everyday life on the Barthel scale above 40 points.

Exclusion: general contraindications (acute inflammatory and febrile diseases, venous thrombosis, unstable arterial hypertension, early condition after contrast computed tomography, early condition after lumbar puncture, general serious condition of the patient); unstable or untreated epilepsy, based on EEG; exacerbation of the main disease (acute psychosis, severe anxiety, tendency to active aggression, etc.); active cancer disease; diseases of the nervous system (neuropathies, stroke, damage to the cerebellum, labyrinth, Parkinson's disease) causing altered sensitivity to stimuli; diseases and illnesses of the musculoskeletal system that disturb the body's balance and the mobility of the limbs; general contraindications (acute inflammatory and febrile diseases, venous thrombosis, unstable arterial hypertension, early condition after contrast computed tomography, early condition after lumbar puncture, general serious condition of the patient); unstable or untreated epilepsy, based on EEG; exacerbation of the main disease (acute psychosis, severe anxiety, tendency to active aggression, etc.); active cancer disease; diseases of the nervous system (neuropathies, stroke, damage to the cerebellum, labyrinth, Parkinson's disease) causing altered sensitivity to stimuli; diseases and illnesses of the musculoskeletal system disturbing body balance and limb mobility; exacerbation of the main disease (acute psychosis, severe anxiety, tendency to active aggression, etc.); mental illnesses other than depression and anxiety disorders; psychotic diseases (F20- schizophrenia and other schizophrenic disorders); general contraindications (acute inflammatory and febrile diseases, venous thrombosis, unstable arterial hypertension, early condition after contrast computed tomography, early condition after lumbar puncture, general serious condition of the patient); unstable or untreated epilepsy, based on EEG; active cancer disease; diseases of the nervous system (neuropathies, stroke, damage to the cerebellum, labyrinth, Parkinson's disease) causing altered sensitivity to stimuli; severe cognitive impairment; diseases and illnesses of the musculoskeletal system that disturb the body's balance and the mobility of the limbs; lack of consent to participate in the study; pregnancy; Adults (men) suffering from schizophrenia, N=40; lack of consent to participate in the study; Adults (women) addicted to alcohol, N= 60; lack of consent to participate in the study; pregnancy; psychoactive substances other than alcohol; diagnosis of autism and ADHD; PTSD; intellectual disability (diagnosis F70 - F79).

Adults suffering from schizophrenia requiring permanent institutional care, N=40.

ClinicalTrials.gov NCT07748078